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Abstract
Background: Information of Previous studies on the prevalence of MS, including our study conducted 12 years
ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS
region in the world Atlas of MS 2013.This study aimed to investigate the prevalence of MS in Mazandaran province
after 12 years and the need for possible changes in the global map of the prevalence of MS.
Methods: We included all MS patients living in Mazandaran province in 2018 in this descriptive cross-sectional study.
We updated our pre-existing registration questionnaires which included demographic information and medical data of
MS patients by interview. We obtained the demographic profile of Mazandaran province from the most recent census
in 2016 and the National Civil Registry of the Mazandaran province for calculating prevalence of MS.
Results: The total number of MS patients in Mazandaran was 2418 (25.8% male and 74.2% female) with a female to
male ratio of 2.9. Based on the local population of 3,332,556, (50.4% male and 49.6% female), this study showed a
prevalence of 72.5 per 100,000 for MS in this region. The prevalence of this disease by gender was 37.1 per 100,000 for
men and 108.5 per 100,000 for women. The mean (SD) age of the patients at the time of the study was 38.5 (10.1)
years with a minimum of 15 and a maximum of 75 years. The most common type of MS was Relapsing-Remitting MS
with 86%.
Conclusions: All recent studies showed significant upward trend in the prevalence of MS around the world. Based on
the results of our study and many other studies in Iran, the Atlas of MS prevalence map needs to be update. Iran’s
status should be changed to the high-prevalence of MS in the new Atlas. Due to the increasing prevalence of MS, we
suggest an adjustment in the Global MS Prevalence Scale.
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Background
The Multiple Sclerosis (MS), as a chronic disease of the
Central Nervous System with a potentially progressive
course, is one of the leading non-traumatic disabling dis-
eases in young adults. Despite its relatively low preva-
lence, MS is accompanied by ponderous socio-economic
effects on communities [1].
Even though some MS patients experience minimal dis-
abilities during their lifetimes, a majority of about 60% of
other MS patients are not without problems within 20
years after the onset of the disease. They experience a var-
iety of complications with significant impacts on their
quality of life and MS has financial burdens on society as
well [2].
Despite the tremendous advances in medical science,
there is no definite treatment for MS, and existing ther-
apies either reduce symptoms or slow down the progres-
sion of the disease by weakening or modulating the
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patients’ immune system, leading to a disease with a
chronic and long-standing course [3]. MS has a signifi-
cant impact on patients and is associated with a wide
range of complications which require appropriate treat-
ment and facilities. Therefore, it is important to have ac-
curate and up-to-date epidemiologic information for
effective planning [4].
Our previous study on the epidemiology of MS in
Mazandaran province of Iran in 2007 showed interesting
results about its prevalence and other epidemiologic in-
dices in this province [4]. According to Kurtzke [5], Iran
has placed in low-MS region in Atlas of the MS 2008
map. The information from our previous study, along
with several other studies in the country [6], led to a
change in Iran’s position in the MS prevalence map in
the World Atlas of MS 2013 to the medium-prevalence
category with 20–60 MS patients in 100,000 population
[7]. (Fig. 1).
MS, as a chronic disease, is expected to have an increas-
ing prevalence. As it was twelve years since the latest
study on the epidemiology of MS in Mazandaran, health
policy makers and directors needed updated information
in this field for MS health planning. This study aims to as-
sess the prevalence of MS in Mazandaran to update the
information for policy making and health planning, and to
provide a basis for future research projects in this field.
The present study seeks an answer to this question: “Is
there a need for a change in the prevalence map of MS in
the world for the second time?”
Study design
In this descriptive-analytical study, trained research as-
sistants updated the demographic and medical informa-
tion of MS registered patients in the MS Society of
Mazandaran province using the standard registration
questionnaire of the MS Society during Face-to-face or
telephone interviews with the patients.
Study population
The target population included patients with a con-
firmed diagnosis of MS who live in Mazandaran Prov-
ince of Iran.
To be eligible for this study, patients needed to
meet all the inclusion criteria and none of the exclusion
criteria below at the time of registration for the study.
Inclusion criteria
1- MS patients registered at the MS Society of
Mazandaran to the end of 2018
2- Capability to provide consent
Exclusion criteria
1- MS patients who were not residents of Mazandaran
province
2- MS patients who were not willing to sign the
consent form for this study
Study method
During the process of registration of patients in the MS
society of Mazandaran province, patients were assessed
at a specialised committee of neurologists and were reg-
istered with a diagnosis of MS based on the 2018 McDo-
nald criteria [8]. All the patients had completed their
questionnaire of the MS Society at the time of registra-
tion. This questionnaire contained demographic (18
items) and disease status questions (12 questions).
Fig. 1 Map of MS prevalence in the world in 2013 [2]
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This project registered and approved at the ethics
committee of Mazandaran University of Medical Sci-
ences, Sari, Iran (Protocol identification number: IR.MA-
ZUMS.REC.1398.4778–4/20/2019). Informed consent
obtained from all patients or their parents/guardians for
those who were minors (age < 18) at the time of registra-
tion in the study for participation and disclosure of their
information without mentioning their names in the re-
search papers. We obtained the written or verbal (if
illiterate) consent from all participants or their parents/
guardians for those who were minors (age < 18) at the
time of registration in their native language (Farsi). This
method was approved by ethics committee of Mazan-
daran University of Medical Sciences, Sari, Iran. When
participants were not capable of signing, written consent
was obtained by fingerprint. The ability to provide con-
sent was an eligibility criterion in this study. All partici-
pants were deemed capable of providing consent by
their primary attendance in Mazandaran Multiple Scler-
osis Society. Patients were granted their right to with-
draw from the study at any time and for any reason.
After the registration for the study, a team of trained re-
search assistants updated the pre-existing data with face-
to-face or telephone interviews with patients, and another
team of research assistant used this data to complete the
electronic case report forms of our database.
We used the demographic data of Mazandaran ob-
tained from the latest results of the 2016 census avail-
able at the website of Statistical Center of Iran [9]. Also,
we obtained the estimation of the population of 2018
from the instant population statistics and forecast of the
year 2018, available at the website of Mazandaran Civil
Registry Office [10] to calculate the prevalence of MS.
After data entry, the study biostatistician used SPSS
version 17 to perform analytical tests and to present the
results as tables and charts. The Kolmogorov-Smirnov
test was implemented to test the normal distribution of
the data. When we needed hypothesis testing, in cases
where the data had a normal distribution, the student t-
test was used and the Kruskal–Wallis test was per-
formed when the data set did not follow a normal distri-
bution pattern.
Results
The population of Mazandaran province at the time of
the study was 3,332,556, of which 1,678,194 (50.4%) were
male, and 1,654,362 (49.6%) were female. The total num-
ber of patients was 2418, of which 623 (25.8%) were
male, and 1795 (74.2%) were female, leading to female to
male ratio of 2.9. The prevalence of MS disease was 72.5
in one hundred thousand population. The prevalence of
the disease by gender was 37.1 in men and 108.5 in
women per one hundred thousand. The mean (SD) age
of the patients at the time of the study was 38.5 (10.1
years) with a minimum of 15 and a maximum of 75
years. The mean (SD) age of patients was 39.2 (10.5) in
men and 38.3 (9.9) years in women. (Fig. 2).
Regarding the marital status, married patients were the
largest group with 1667 people (68.9%) while widows or
widowers with 30 people (1.2%) was the smallest group.
A large proportion of patients, (61%) had literacy levels
of High school diploma to bachelor’s degree, and a sig-
nificant per cent (29.8%) had an education level of pri-
mary school to high school diploma. The birthplace of
42% of the patients were rural areas from which 50%
moved to urban areas subsequently. Only 301 (12.4%) of
MS patients mentioned a history of immigration in their
lives, with (62.1%) of them immigrating after the age of
15 years old. The complete demographic data of patients
are shown in Table 1.
Of the total number of patients, 2079 (86%) had a
relapsing-remitting type of MS, and the progressive-
relapsing type with 3 cases (0.1%) had the lowest num-
ber. The mean age (SD) of the initial symptom presenta-
tion was 28.7 (8.6) years, with a minimum of 6 and a
maximum of 63 years. The most common symptom was
visual disturbances (34.5%) and sensory problems
(27.6%), and nearly 10% of the patients had 2 or more
symptoms. (Fig. 3).
Average elapsed time for reaching a final diagnosis
was 15 days with a maximum of 20 years and a mini-
mum of 3 days, and the difference in the time elapsed
from the initiation of symptoms to the diagnosis of MS
was not significant between men and women. Approxi-
mately 60% of patients reported having one or two hos-
pital admissions only due to MS, while nearly one-third
of the patients (33.5%) had no history of hospital admis-
sion, because they received out of hospital medical ser-
vices. Most of the patients (88.5%) mentioned the
history of MS in a non-close relative while only 52 pa-
tients (2.2%) had no family history of MS. (Fig. 4).
1941(80.3%) patients did not have any other health
conditions and, rheumatologic diseases with a rate of
11.3%, were the most commonly associated co-
morbidities. That was significantly greater in women
(p < 0.05). The history of motor vehicle accidents before
the occurrence of MS was 8.4, and 41.2% of patients had
a history of surgery, while only a few patients
(110(4.5%)) had blood transfusion or blood products
usage history before the diagnosis of MS.
Discussion
Over the past 10 years, there have been many epidemio-
logical studies on MS in Iran indicating an increase in
the prevalence of MS. Initial studies took place in
Isfahan and Mazandaran provinces. The prevalence of
MS was 20.1 per 100,000 people in Mazandaran Prov-
ince (582 cases) in 2007. The average age of patients was
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Fig. 2 Distribution of MS patients by sex
Table 1 Demographic Information of MS Patients in Mazandaran Province in 2018
Male Female Total (percent) row
No. % No. % No. %
Patients with MS in Mazandaran Province 623 25.8% 1795 74.2% 2418 100%
Marital status Single 198 8.2% 442 18.3% 640 26.5%
Married 412 17% 1255 51.9% 1667 68.9%
Widow or Widower 1 a0.0% 29 1.2% 30 1.2%
Divorced 12 0.5% 69 2.9% 81 3.4%
Education level Illiterate 14 0.6% 92 3.8% 106 4.4%
Elementary or lower than diploma 218 9% 503 20.8% 721 29.8%
Diploma 152 6.3% 515 21.3% 667 27.6%
Undergraduate 198 8.2% 610 25.2% 808 33.4%
Master’s degree or higher 41 1.7% 75 3.1% 116 4.8%
Immigration history Before 15 years old 25 8.3% 89 0.3% 114 37.8%
15 years old or older 39 13% 148 49.2% 187 62.2%
Birth place City 339 14% 1070 44.3% 1409 58.2
Village 284 11.7% 725 30% 1009 41.7%
Current residence City 433 17.9% 1299 53.7% 1732 71.6%
Village 190 7.9% 496 20.5% 686 28.4%
aBecause of displaying numbers up to one-tenth of decimal places, the numerical value obtained is zero
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Fig. 3 Frequency of symptoms at the onset of MS
Fig. 4 Family history of MS patients
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34.3 years, and the female to male ratio was 2.6 [4]. In
the present study, it can be seen that the prevalence of
MS in Mazandaran is 72.5 per 100,000 people, which
shows an increase of roughly 3.5 times. The average age
of the patients increased 4 years and reached to 38.5,
and the ratio of women to men, by 0.3 increase, esti-
mated at 2.9.
In Isfahan province which is located in central Iran,
the prevalence of MS disease was 35.5 per 100,000 in
2006, and the average age of the patients was 32.5 years
with a female to male ratio of 3.6 [6]. A more recent
study in 2014 showed a 1.5-fold increase in the preva-
lence of this disease with 54.5 MS patients per 100,000
and a drop in the sex ratio of 0.3 since 2006 in the same
region [11]. There was no MS patient under 15 years
old. These findings suggest potential role of puberty
period on the onset of pathogenesis of MS that noted in
another study as well [12].
In 2009, a research project on MS showed a preva-
lence of 50.57 in 100,000 people for this disease in
Tehran. The female to male ratio was 3.1 l, and the
mean age of MS patients was 35.48 years in this study
[13]. Izadi found the prevalence of 72.1 in 100,000
people in Fars province in 2015 for this disease with fe-
male to male ratio of 4.04 (a prevalence of 116.5 in
women and 28.3 in men) [14]. A review article, pub-
lished in “the International Journal of Epidemiologic Re-
search” in 2018, showed a sharp increase in the
prevalence of MS up to 95 per one hundred thousand
since 2013 [15].
Our study showed a lower prevalence for MS in
Mazandaran compared to other provinces of Iran with a
lower latitude while, we expected Mazandaran, as a
northern province, to have a higher prevalence of MS.
Different factors can be contributing to a relatively lower
estimation of the prevalence of MS in Mazandaran des-
pite its higher latitude. One possible explanation for this
difference can be the referral pattern of patients of
neighbouring provinces to the study centres to access
tertiary healthcare facilities. Because of the proximity of
Mazandaran province to Tehran, the capital of Iran, with
a significantly higher number of health care facilities, we
can see a tendency in Mazandaran MS patients to follow
their treatment in Tehran. Additionally, Rasht, the cap-
ital of Gilan province, might be more accessible for some
of the patients in the western regions of Mazandaran.
Numerous studies have reported a similar increasing
trend in the prevalence of MS in many other countries
around the world. In 2002, Pugliatti et al. estimated the
prevalence of MS in northern and western Europe to be
under 170 per 100,000 population [16]. This figure in-
creased to more than 200 in one hundred thousand in
Kingwell et al. study in 2013 [17].. In Canada, there has
been a dramatic increase in the prevalence of MS from
157 in 1996 to 265 per hundred thousand population in
2013 [18]. In the United States, the MS prevalence rate
was estimated at 85 per 100.000 people in 2002 [19],
while, 8 years later, studies conducted in three different
regions of the United States, showed an increase of up
to 109 per 100,000 population in the prevalence of this
disease [20].
Although these findings hypothesized the sunlight and
UV role in the pathogenesis of MS, but many studies did
not support this hypothesis. In the study of Ofer Amram
and et al., the life time UVB exposure estimated by new
satellite technology [21]. There was no significant asso-
ciatiation between the age MS onset and calculated UVB
exposure [22].
Conclusions
Repeated studies over the years have indicated a signifi-
cant upward trend in the prevalence of MS throughout
the world.
Concerning the current prevalence of MS in Mazan-
daran province along with other parts of Iran, changes
in MS World Map will be expected. In the new release
of the MS World Map, Iran is expected to be placed in
the high-prevalence area category. Moreover, recent
changes in the prevalence of MS in the rest of the world
may result in further changes in this map.
Significant increase in the prevalence of MS in the
World, suggests a new grouping in the Global MS Preva-
lence Scale. We recommend to categories countries by
prevalence as follows: lower than 5 in 100,000 as an area
of Very-low-prevalence, 5 to 20 in 100,000 as a low-
prevalence-area, 20 to 100 in 100,000 as a medium-
prevalence area, 100 to 180 in 100,000 as an area of high
prevalence and above 180 in 100,000 as a very-high-
prevalence area.
Recently introduced more effective medications has re-
sulted in reduced or controlled progression of MS and
prolongation of the duration of this disease. This in-
crease in the life expectancy of MS patients leads to the
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